Although recent improvements have been indicated in the outcome after allogeneic hematopoietic cell transplantation (allo-HCT), little information is available on how changes in transplant modalities have affected the outcomes after allo-HCT in non-remission, based on patient age, donor source and disease type. We compared the incidence and causes of non-relapse mortality (NRM) after allo-HCT in non-remission among three consecutive four-year periods using a nationwide transplant outcome registry database. A total of 3308 patients with acute leukemia in non-remission were analyzed. The risk of NRM decreased over the three periods, and the hazard ratios (HRs) in 2001-2004 and 2005-2008 compared with 1997-2000 were 0.86 (95% CI, 0.70-1.06; P ¼ 0.16) and 0.65 (95% CI, 0.53-0.80; Po0.01), respectively. A significant decrease in the HR for overall mortality was also observed in [2005][2006][2007][2008] (HR 0.85; 95% CI, 0.75-0.97; P ¼ 0.02). We found that a decrease in the incidences of death due to GVHD and infection contributed to the reduction in NRM, to which high-resolution donor-recipient HLA matching and other improvements may have contributed. As none of the subgroups showed improved survival without a reduction in NRM, the effective prevention of transplant-related complications appears to be necessary for improving outcomes after allo-HCT in non-remission. Keywords: allogeneic hematopoietic cell transplantation; acute leukemia; non-remission; non-relapse mortality; GVHD INTRODUCTION Allogeneic hematopoietic cell transplantation (allo-HCT) is recognized as a potentially curative therapy for patients with high-risk hematologic malignancies, which can lower the risk of relapse. However, treatment-related mortality, which may offset the benefit of a reduced risk of relapse, has long been a major problem. Several changes have been made in modalities of allo-HCT, including patient-donor HLA matching, conditioning regimens, immunosuppressive therapy, and the prophylaxis, diagnosis and treatment of GVHD and infection. As a result, the risk of non-relapse mortality (NRM) after allo-HCT has decreased over the past few decades.
INTRODUCTION
Allogeneic hematopoietic cell transplantation (allo-HCT) is recognized as a potentially curative therapy for patients with high-risk hematologic malignancies, which can lower the risk of relapse. However, treatment-related mortality, which may offset the benefit of a reduced risk of relapse, has long been a major problem. Several changes have been made in modalities of allo-HCT, including patient-donor HLA matching, conditioning regimens, immunosuppressive therapy, and the prophylaxis, diagnosis and treatment of GVHD and infection. As a result, the risk of non-relapse mortality (NRM) after allo-HCT has decreased over the past few decades. [1] [2] [3] [4] [5] [6] AML and ALL account for the largest proportion of diseases indicated for allo-HCT. Furthermore, a substantial number of patients with AML or ALL receive allo-HCT in non-remission. Despite the fact that high-risk acute leukemia is definitely indicated for allo-HCT, patients with non-remission leukemia carry various factors that lead to a higher risk of treatment-related toxicity, including comorbidities due to prior chemotherapy and intensified conditioning regimens in need of an antitumor effect, [7] [8] [9] [10] [11] and a deteriorated general condition due to refractory disease. Although prior studies have shown improvements in the outcome after allo-HCT, [1] [2] [3] [4] [5] little information is available on how changes in transplant modalities have affected the outcomes after allo-HCT in non-remission, based on patient age, donor source and disease type. We recently reported changes in the incidence and causes of NRM after allo-HCT in remission in Japan. 6 Using the same nationwide transplant outcome registry database, we compared the incidence and causes of NRM in patients with AML or ALL in nonremission in three consecutive four-year periods.
SUBJECTS AND METHODS

Data source
Clinical data were extracted from a nationwide transplant outcome registry database provided by the Japan Society for Hematopoietic Cell Transplantation, the Japan Marrow Donor Program and the Japan Cord Blood Bank Network, to which 267 institutions/departments contributed. The clinical data were consecutively collected through Transplant Registry Unified Management Program as described previously. 12 This study was 1 approved by the data management committees of the Japan Society for Hematopoietic Cell Transplantation, the Japan Marrow Donor Program and the Japan Cord Blood Bank Network, and by the Institutional Review Board at the National Cancer Center Hospital.
Patients and definitions
We evaluated data on patients aged between 16 and 70 years who had AML or ALL and who received their first allo-HCT in non-remission between 1997 and 2008. Non-remission status was defined as any percentage of blasts in the peripheral blood, or a BM aspirate containing 45% blasts at the time of transplant. We compared the incidence of NRM after allo-HCT in three consecutive four-year periods (1997-2000, 2001-2004 and 2005-2008) for younger patients (16-49 years) , and in the latter two periods for older patients (50-70 years). NRM was defined as death without the detection of recurrent disease after allo-HCT. In 154 patients who died without a confirmed hematological remission within 30 days from allo-HCT, the cause of death was defined as NRM. In 293 patients who died without a confirmed hematological remission after 31 days or later after allo-HCT, the cause of death was defined as refractory disease. A separate analysis that excluded these 447 patients who died without a confirmed remission was performed. We also changed the cutoffs from 30 days to 60 days or 90 days. Analyses were performed on the basis of patient's age (16-49 years and 50-70 years), disease (AML and ALL) and donor source (HLA-matched/1-Ag-mismatched related, unrelated BM and unrelated cord blood (CB)). In this study, matching of unrelated BM between recipient and donor were determined based on serum typing. In 2003, Japan Marrow Donor Program nationally recommended DNA typing of HLA-A and B, as well as HLA-DRB1. Since 2005, Japan Marrow Donor Program required all the candidates of unrelated allo-HCT to examine high-resolution typing of HLA-A, B and DRB1 and also recommended high-resolution typing of C-locus. In the era considered by this study, only BM was used from unrelated volunteer donors in Japan. Conditioning regimens were classified as indicated by Giralt et al. 13 The causes of death other than recurrent disease were obtained from the database and the incidences of mortality associated with GVHD, infection or organ failure were compared over the three time periods. In patients who had multiple causes among GVHD, infection and organ failure, information regarding the main cause of death was prioritized. The 447 patients who died without a confirmed hematological remission were excluded from the analyses regarding the causes of death.
Statistical analysis
Data were retrospectively reviewed and analyzed as of March 2012. Among the three time periods, patient characteristics were compared using the w 2 -test. The primary endpoint of the study was NRM after allo-HCT. Probabilities of NRM were estimated with the use of cumulative incidence curves, with relapse viewed as a competing risk of NRM. The Pepe and Mori test was used to evaluate the differences between groups. For the 337 patients (10%) who were known to have relapsed but whose date of relapse was unavailable, midpoint imputation was performed by substituting the midpoint from HCT to date of last contact as the date of relapse. The incidence of NRM was estimated as the probability at 2 years from allo-HCT. Multivariate analyses were performed for NRM and relapse using competing risk regression by the method of Fine and Gray, and for survival using a Cox proportional hazard regression model. The analyses were performed separately among younger patients aged 16-49 years and older patients aged 50-70 years. In the multivariate analyses, we considered the following factors as covariates: the year of allo-HCT Multivariate analyses were also performed separately for patients who received related allo-HCT, patients who received unrelated BMT (UBMT), and patients who received UCBT. We considered two-sided P-values of o0.05 to be statistically significant. Statistical analyses were performed with SAS version 9.1.3 (SAS, Cary, NC, USA) and SPSS software version 11.0.1 (SPSS, Chicago, IL, USA).
RESULTS
Patients
A total of 3308 patients with a median age of 42 years and a median follow-up of 27 months (range, 0-150) was analyzed. The characteristics of the patients and transplantation procedures according to the time period are shown in Table 1 (5) 83 (7) 85 (6) Unrelated CB 23 (4) 176 (15) (26) 173 (11) Abbreviation: CB ¼ cord blood.
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Transplant outcomes Overall, the incidence of NRM was 31% at 2 years after allo-HCT ( Figure 1a) . Patients who were 50 years or older had a significantly higher incidence of NRM than patients who were 49 years or younger (39% vs 28%, Po0.001, Figure 1b) . The donor source significantly affected the incidence of NRM, and unrelated CB had the highest risk of NRM (related, 23%; unrelated BM, 33%; unrelated CB, 42%, Po0.001, Figure 1c Younger age and HLA-matched sibling donor were also significantly associated with reduced overall mortality. Although the HR for NRM in the RIC group tended to be higher than that in the myeloablative group (HR 1.20; 95% CI, 0.99-1.47; P ¼ 0.07), this difference was NS. An analysis according to disease type showed that the HRs for NRM and overall mortality were reduced in AML patients, but not in ALL patients ( Table 2) Transplant outcomes based on donor We also performed analyses based on the donor source separately among younger and older patients (Table 3 ). In related donor transplantation, there were no differences in the HRs for NRM, relapse and OS among the time periods in both younger and older patients. In younger patients who received UBMT, there were Causes of death that accounted for changes in NRM The causes of death were obtained in 98% of patients who died without recurrent disease. In 17% of patients for whom multiple causes of death were provided, GVHD, infection, or organ failure given as a main cause of death was prioritized. Overall, 151 patients died of acute or chronic GVHD (median OS: 101 days, range: 12-1979), 337 died of infection (median OS: 63 days, range: 1-2700), and 251 died of organ failure (median OS: 88 days, range: 0-2283). In the overall population, no remarkable decrease in the incidences of mortality due to these three causes was observed although the HRs for NRM and overall mortality decreased (Table 2) . Meanwhile, significant reductions in the incidences of GVHD-related and infection-related mortality were observed among younger patients who received UBMT (Figure 2a ) and UCBT (Figure 2b ). In older patients or allo-HCT from a related donor, no remarkable differences were observed in the incidences of mortality due to GVHD, infection or organ failure among the time periods. The incidence of organ failure-related mortality did not decrease in any of the subgroups.
DISCUSSION
We evaluated the changes in NRM after allo-HCT for acute leukemia in non-remission over the last 12 years. Overall, we found higher NRM rates compared with those after allo-HCT in remission (31 vs 22% at 2 years after HCT). 6 The HRs for NRM and overall mortality were lower in more recent time periods. Although several studies have shown changes in outcomes after allo-HCT, [1] [2] [3] [4] [5] [6] this is the first analysis restricted to allo-HCT in nonremission, based on the patient age, donor source and disease type. The reduction in the HR for NRM was reflected in the reduced HR for overall mortality, and none of the subgroups showed a reduced risk for overall mortality without an improvement in NRM. This may indicate that lowering the risk of treatment-related mortality is, so far, an absolute requirement for improving outcomes after allo-HCT in non-remission, where a high-risk of relapse has always been an obstacle.
The reductions in the HRs for NRM and overall mortality in the overall population were accounted for by the reductions in HRs in patients with AML, and there was no improvement in NRM or overall mortality in those with ALL in non-remission over the three time periods. We also found that the number and proportion of patients who received allo-HCT for ALL in non-remission decreased over the three time periods despite an increase in the total number of allo-HCT. The proportions of both Ph-positive ALL and Ph-negative ALL decreased and, interestingly, more patients with Ph-positive ALL have received allo-HCT in remission after 2000. The introduction of imatinib may have helped more patients with Ph-positive ALL to receive allo-HCT in a controlled disease status. [14] [15] [16] In addition, a lowered expectation for the effect of allo-HCT in ALL in non-remission may have also impacted the indication. In patients who receive allo-HCT in non-remission, strategies that can provide intensified preparative regimens and a GVL effect without increasing toxicity need to be pursued.
No improvement in the HRs for NRM and overall mortality was observed in patients aged 50-70 who received allo-HCT in nonremission. Older patients with acute leukemia have been reported to have a worse prognosis because of more unfavorable disease profiles, deteriorated general conditions and an increased risk of comorbidities. 17 As the eradication of residual disease by provoking GVHD may increase toxicity and become unbearable for elderly patients, it may be necessary to reduce the tumor burden before transplantation. We previously demonstrated a significant reduction in NRM in patients aged 50 years or older who received allo-HCT in remission. 6 The safety and efficacy of modified induction chemotherapy or preparative regimen for elderly patients need to be validated. [18] [19] [20] [21] [22] [23] [24] [25] We found that decreases in GVHD-related and infection-related mortality contributed to the reduced risk of NRM. These findings are consistent with prior reports. 2, 3 Based on an analysis of 14 403 patients with leukemia in the first CR who received allo-HCT from a matched sibling donor, Gratwohl et al. 3 showed that the rate of mortality due to infection decreased. In a detailed analysis in a single-center study, Gooley et al. 2 showed that the rates of severe GVHD and infection were recently reduced. There have been substantial improvements in HLA typing over the period of 1997-2008, with more accuracy in defining HLA haplotypes at highresolution. 26, 27 In addition to high-resolution donor-recipient HLA matching, the more frequent use of tacrolimus, [28] [29] [30] the prompt initiation of treatment after a more thorough examination to diagnose GVHD, 31 and supportive care and nutritional management 32 may have contributed to the reduced risk of GVHD-related mortality as did in allo-HCT in remission. Alternatively, the unique HLA epidemiological genetics of Japanese patients may have affected the results. 33, 34 As GVHD and infection have been reported to be associated with each other's development and exacerbation, [35] [36] [37] an improved control of severe GVHD, along with the introduction of new antifungal drugs, may have led to the reduction of the risk of infection-related mortality. We did not find a reduction in the risk of organ failure-related mortality in any of the subgroups. Although intensified antitumor treatment may be required in allo-HCT in non-remission, continuous effort is needed for monitoring, prevention and intervention with regard to regimen-related toxicity, including late effects. [38] [39] [40] As this analysis is based on a retrospectively collected multicenter database, our results may be susceptible to the disadvantages of any retrospective study using a multicenter registry database. In patients who died without a confirmed hematological remission, we assumed the disease status from the survival time.
The impact on transplant outcome of detailed disease status in non-remission patients 41 was not assessed because of the lack of information. In addition, detailed data regarding the incidences of infection or other complications were not available. While we acknowledge these limitations, our data showed that the risks of NRM have decreased after allo-HCT for patients with acute , and conditioning regimens (myeloablative versus reduced-intensity) were considered as covariates. In the analysis for AML and ALL, the 5 covariates were considered other than disease type.
NRM after allo-HCT in non-remission S Kurosawa et al , and conditioning regimens (myeloablative vs reduced-intensity) were considered as covariates. In the analysis for related HCT, HLA-matched sibling vs other family donors were considered as covariates in donor source in addition to the other five factors. In the analysis for unrelated BMT, HLA-matched BM vs mismatchedunrelated BM were considered as covariates in donor source in addition to the other five factors. In the analysis for unrelated CB transplantation, the five covariates were considered other than the donor source. leukemia in non-remission, using a large nationwide consecutive data. In subgroups that showed a reduced risk of NRM, significant reductions in the incidences of GVHD-and infection-related mortality were observed. We also indicated that there has been no decrease of NRM in older patients or in related donor transplant. In addition, our study showed that non-remission ALL continues to remain a major challenge. As none of the subgroups showed improved survival without a reduction in the HR for NRM, not only the control of refractory disease but also effective prevention, monitoring and treatment of transplant-related complications may be necessary to improve outcomes after allo-HCT in non-remission. Our findings may provide a foundation for future studies to improve outcomes of allo-HCT for acute leukemia in non-remission.
